Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Overview

About this study

The purpose of this study is to evaluate how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is:  negative for RAS wild-type colorectal cancer and has spread to other places in the body, and/or cannot be removed by surgery, and is negative for resistance mutations in blood. Treatment with panitumumab may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors to keep growing. Growth factor antagonists, such as regorafenib, may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab may work better in treating patients with colorectal cancer than with the usual treatment of regorafenib or TAS-102.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Registered to Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly
Assigned Therapy (COLOMATE) ACCRU-GI-1611 and:

- COLOMATE Companion Trial Recommendation Form indicates patient qualifies to be
screened for a COLOMATE companion trial.

- COLOMATE Companion Trial Recommendation Form date of completion is =< 30 days
prior to randomization.

- Histologically and/or cytologically confirmed adenocarcinoma of the colon or rectum
that is metastatic and/ or unresectable.

- Documented wild-type in KRAS and NRAS (codons 12, 13, 59, 61, 117, and 146) and in
BRAF codon 600, based on tumor tissue taken from primary or metastatic site prior to
receipt of anti EGFR therapy.

- Progression, intolerance, or contraindication to a fluoropyrimidine (e.g.,
5-fluorouracil or capecitabine), oxaliplatin, irinotecan, and an anti-VEGF monoclonal
antibody (bevacizumab, ramucirumab, or aflibercept), and an anti-PD-1 monoclonal
antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins
(dMMR) or is microsatellite instability-high (MSI-H)

- Disease progression after treatment with an anti-EGFR monoclonal antibody (cetuximab
and/or panitumumab) for at least 4 months (minimum of 8 biweekly treatments or 16
weekly treatments at full or partial dose).

- NOTE: Treatments do not need to be administered consecutively.

- NOTE: Dose reductions or delays are permitted.

- Greater than 90 days has elapsed between the most recent treatment with an anti-EGFR
therapy (cetuximab or panitumumab) and blood collection for COLOMATE ACCRU-GI-1611.

- At least one site of disease that is measurable by Response Evaluation Criteria in
Solid Tumors (RECIST) criteria that has not been previously irradiated; if the patient
has had previous radiation to the target lesion(s), there must be evidence of
progression since the radiation.

- Life expectancy >= 3 months per estimation of investigator.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1, or 2.

- Absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
(obtained =< 7 days prior to randomization).

- Platelet count >= 75,000 /mm^3 (obtained =< 7 days prior to randomization).

- Hemoglobin > 8.0 g/dL (obtained =< 7 days prior to randomization).

- Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to
randomization).

- Aspartate transaminase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver
involvement of their cancer) (obtained =< 7 days prior to randomization).

- Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN for subjects with liver
involvement of their cancer) (obtained =< 7 days prior to randomization).

- Calculated creatinine clearance must be > 30 ml/min using the Cockcroft-Gault formula
(obtained =< 7 days prior to randomization).

- Women of child bearing potential and male partners of women of child bearing potential
must agree to use two medically accepted methods of contraception, one of them being a
barrier method during the study and for 2 months after the last dose of study drug(s).

- Negative serum pregnancy test done =< 7 days prior to randomization, for women of
childbearing potential only.

- NOTE: Women of childbearing potential include women who have experienced menarche
and who have not undergone successful surgical sterilization (hysterectomy,
bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal.
Postmenopause is defined as amenorrhea >= 12 consecutive months. NOTE: women who
have been amenorrheic for 12 or more months are still considered to be of
childbearing potential if the amenorrhea is possibly due to prior chemotherapy,
anti-estrogens, ovarian suppression or any other reversible treatment.

- Ability to complete questionnaire(s) by themselves or with assistance.

- Capable of understanding and complying with the protocol requirements and has signed
the informed consent document.

- Willing to return to enrolling institution for follow-up (during the active monitoring
phase of the study).

- Willing to provide tissue and blood samples for correlative research purposes.

- Willing to allow transfer of tissue and blood samples, clinical information, and
outcome data collected from this trial for future research.

Exclusion Criteria:

- Radiation therapy, hormonal therapy, biologic therapy, experimental therapy, or
chemotherapy for cancer < 21 days prior to randomization.

- Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin).

- Maximum mutant allele frequency (highest allele frequency reported for any gene
mutation) (MAF) less than 2% by Guardant360 assay.

- Detection of at least one of the following gene mutation(s) or amplification(s) by
Guardant360 assay.

- BRAF mutation mutant allele frequency (MAF) > 0.5%.

- EGFR mutation (MAF > 0.5%). Note: EGFR S492R, K467, and R451C mutations are not
an exclusion.

- ERBB2 (HER2) mutation (MAF > 0.5%) or amplification.

- KRAS mutation (MAF > 0.5%) or amplification.

- MET mutation (MAF > 0.5%) or amplification.

- NRAS mutation (MAF > 0.5%) or amplification

- Prior treatment with both TAS-102 and regorafenib (prior treatment with either TAS-102
or regorafenib is permitted).

- Unable to swallow oral tablets (crushing of study treatment tablets is not allowed).

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for entry into this study or
interfere significantly with the proper assessment of safety and toxicity of the
prescribed regimens. Note: This includes impaired heart function or clinically
significant heart disease.

- Not recovered to baseline or Common Terminology for Adverse Events (CTCAE) version
(v)5.0 =< grade 1 from toxicity due to all prior therapies except alopecia,
oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities, and other
non-clinically significant adverse events.

- Any of the following because this study involves an agent that has known genotoxic,
mutagenic and teratogenic effects:

- Pregnant women.

- Nursing women.

- Men or women of childbearing potential who are unwilling to employ adequate
contraception.

- Patients with known central nervous system (CNS) metastases. Note: Patients with
radiated or resected lesions are permitted, provided the lesions are fully treated and
inactive (based on repeat imaging >= 30 days after completion of definitive
treatment), patients are asymptomatic, and no steroids to control symptoms related to
CNS metastases have been administered for at least 30 days.

- Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days
prior to randomization (=< 56 days for hepatectomy, open thoracotomy, major
neurosurgery) or anticipation of need for major surgical procedure during the course
of the study.

- Serious, non-healing wound, ulcer, or bone fracture.

- History of stroke (cerebrovascular accident), transient ischemic attack (TIA),
myocardial infarction (MI), unstable angina, cardiac or other vascular stenting,
angioplasty, or cardiac surgery =< 6 months prior to randomization.

- History of cardiac arrhythmias requiring anti-arrhythmic therapy other than beta
blockers, calcium channel blockers, or digoxin =< 6 months prior to randomization.

- Known history of congestive heart failure - New York Heart Association (NYHA) >= class
II.

- Known history of human immunodeficiency virus (HIV) seropositivity, acute or chronic
active hepatitis B or C infection, or other serious chronic infection requiring
ongoing treatment.

- History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or
evidence of interstitial lung disease on baseline chest computed tomography (CT) scan.

- Subjects with any previously untreated or concurrent cancer that is distinct in
primary site or histology from colorectal cancer except cervical cancer in-situ,
treated basal cell carcinoma, or superficial bladder tumor. Note: Subjects surviving a
cancer that was curatively treated and without evidence of disease or biochemical
relapse (undetectable PSA for prostate cancer) for 3 or more years before
randomization are allowed. All cancer treatments must be completed at least 3 years
prior to randomization.

- Uncontrolled hypertension (systolic pressure > 150 mm HG or diastolic pressure > 90 mm
Hg [National Cancer Institute (NCI)-CTCAE v5.0]) on repeated measurement despite
optimal medical management.

- Evidence or history of bleeding diathesis or coagulopathy.

- Any hemorrhage or bleeding event >= NCI CTCAE v5.0 grade 3, =< 4 weeks prior to
randomization.

- Ongoing active infection > grade 2 NCI-CTCAE v5.0.

- Known or suspected allergy or hypersensitivity to any of the study drugs, study drug
classes, or excipients of the formulation given during the course of this trial.

- EXCEPTION: Cetuximab

- Any known history of malabsorption condition.

- Substance abuse, medical, psychological or social conditions that may interfere with
the subject's participation in the study or evaluation of the study results.

- Use of any herbal remedy (e.g. St. John's wort) =< 7 days prior to randomization.

- Use of strong CYP3A4 inducers or inhibitors =< 7 days prior to randomization.

Eligibility last updated 5/25/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Zhaohui Jin, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Jeremy Jones, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20478655

Mayo Clinic Footer